SGAM
GNCA

Smith Group Asset Management’s Genocea Biosciences, Inc. GNCA Stock Holding History

Smith Group Asset Management’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-12,984
Closed -$712K – 529
2015
Q3 		$712K Sell
12,984
-20
-0.2% -$1.98K 0.03% 184
2015
Q2 		$1.43M Buy
+13,004
New +$1.21M 0.05% 159

Other funds holding GNCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Smith Group Asset Management's GNCA Position: Q4 2015 in Review

Smith Group Asset Management sold out of Genocea Biosciences, Inc. (GNCA) in Q4 2015, closing a stake of 12,984 shares — an estimated $712K sold.

Smith Group Asset Management first reported a position in GNCA in Q2 2015 and held it in 2 quarters. The position peaked at $1.43M in Q2 2015. 57 funds tracked by Wall St. Rank hold GNCA as of Q4 2015.

  • Smith Group Asset Management reported no remaining Genocea Biosciences, Inc. position as of Q4 2015 after selling out during the quarter.
  • Smith Group Asset Management sold 12,984 Genocea Biosciences, Inc. shares in Q4 2015, an estimated $712K.
  • Smith Group Asset Management first reported a position in Genocea Biosciences, Inc. in Q2 2015 and held it in 2 quarters.
  • Smith Group Asset Management's Genocea Biosciences, Inc. position peaked at $1.43M in Q2 2015.
  • 57 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q4 2015.

Based on Smith Group Asset Management's 13F filing for Q4 2015, filed 3 Feb 2016.